128 related articles for article (PubMed ID: 22910125)
1. An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.
Lahoz A; Vilà MR; Fabre M; Miquel JM; Rivas M; Maines J; Castell JV; Gómez-Lechón MJ
Toxicol In Vitro; 2013 Jun; 27(4):1410-5. PubMed ID: 22910125
[TBL] [Abstract][Full Text] [Related]
2. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.
Tolosa L; Gómez-Lechón MJ; Pérez-Cataldo G; Castell JV; Donato MT
Arch Toxicol; 2013 Jun; 87(6):1115-27. PubMed ID: 23397584
[TBL] [Abstract][Full Text] [Related]
3. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment.
Tolosa L; Donato MT; Pérez-Cataldo G; Castell JV; Gómez-Lechón MJ
Toxicol In Vitro; 2012 Dec; 26(8):1272-7. PubMed ID: 22138474
[TBL] [Abstract][Full Text] [Related]
4. Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.
Gómez-Lechón MJ; Tolosa L; Donato MT
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):137-148. PubMed ID: 27671376
[TBL] [Abstract][Full Text] [Related]
5. NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.
Schulz C; Kammerer S; Küpper JH
Clin Hemorheol Microcirc; 2019; 73(1):249-260. PubMed ID: 31561354
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells.
Dai Y; Cederbaum AI
J Pharmacol Exp Ther; 1995 Jun; 273(3):1497-505. PubMed ID: 7791125
[TBL] [Abstract][Full Text] [Related]
7. Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo.
Donato MT; Hallifax D; Picazo L; Castell JV; Houston JB; Gomez-Lechón MJ; Lahoz A
Drug Metab Dispos; 2010 Sep; 38(9):1449-55. PubMed ID: 20501911
[TBL] [Abstract][Full Text] [Related]
8. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Vignati L; Turlizzi E; Monaci S; Grossi P; Kanter Rd; Monshouwer M
Toxicology; 2005 Dec; 216(2-3):154-67. PubMed ID: 16169652
[TBL] [Abstract][Full Text] [Related]
9. In vitro micronucleus test in HepG2 transformants expressing a series of human cytochrome P450 isoforms with chemicals requiring metabolic activation.
Hashizume T; Yoshitomi S; Asahi S; Matsumura S; Chatani F; Oda H
Mutat Res; 2009; 677(1-2):1-7. PubMed ID: 19501186
[TBL] [Abstract][Full Text] [Related]
10. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
12. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells.
Zahno A; Brecht K; Morand R; Maseneni S; Török M; Lindinger PW; Krähenbühl S
Biochem Pharmacol; 2011 Feb; 81(3):432-41. PubMed ID: 21070748
[TBL] [Abstract][Full Text] [Related]
13. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium.
Lakehal F; Wendum D; Barbu V; Becquemont L; Poupon R; Balladur P; Hannoun L; Ballet F; Beaune PH; Housset C
Hepatology; 1999 Dec; 30(6):1498-506. PubMed ID: 10573530
[TBL] [Abstract][Full Text] [Related]
14. HepG2 cells: an in vitro model for P450-dependent metabolism of acetaminophen.
Roe AL; Snawder JE; Benson RW; Roberts DW; Casciano DA
Biochem Biophys Res Commun; 1993 Jan; 190(1):15-9. PubMed ID: 8380689
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
Gillani TB; Rawling T; Murray M
Chem Res Toxicol; 2015 Jan; 28(1):92-102. PubMed ID: 25489883
[TBL] [Abstract][Full Text] [Related]
17. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.
Tolosa L; Jiménez N; Pérez G; Castell JV; Gómez-Lechón MJ; Donato MT
Arch Toxicol; 2018 Jan; 92(1):383-399. PubMed ID: 28762043
[TBL] [Abstract][Full Text] [Related]
18. Modulatory actions of o-coumaric acid on carcinogen-activating cytochrome P450 isozymes and the potential for drug interactions in human hepatocarcinoma cells.
Sen A; Terzioglu G; Atmaca P; Celik G; Ozgun O; Arslan S
Pharm Biol; 2015; 53(9):1391-8. PubMed ID: 25880144
[TBL] [Abstract][Full Text] [Related]
19. Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line.
Matuo MC; de Oliveira Takamoto RT; Kikuchi IS; de Jesus Andreoli Pinto T
Cell Biol Int; 2013 Aug; 37(8):843-8. PubMed ID: 23554079
[TBL] [Abstract][Full Text] [Related]
20. Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Rana P; Will Y; Nadanaciva S; Jones LH
Bioorg Med Chem Lett; 2016 Aug; 26(16):4003-6. PubMed ID: 27397500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
